BHC INVESTOR DEADLINE APPROACHING: Robbins Geller Rudman & Dowd LLP Announces that Bausch Health Companies Inc. Investors with Substantial Losses Have Opportunity to Lead Case Pharmaceutical Investing
Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia & Company Psychedelics Investing
Final Deadline Approaching for Bausch Health Companies Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Bausch Health Companies Inc. Investors of September 25, 2023 Lead Plaintiff Deadline Pharmaceutical Investing
New Bausch Health Treatment PrUCERIS Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults Pharmaceutical Investing
Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution , 100 mg/mL due to Crystallization Life Science Investing
Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA Pharmaceutical Investing
BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer Geography
Bausch Health's Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA Pharmaceutical Investing
BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders Geography
